

AZATHIOPRINE 50 mg/mL ORAL SUSPENSION

Date Prepared: / / 20			LOT: NS				
Expiry Date: / / 20			Final Checked By:				
INGREDIENTS	MFR	LOT #	EXPIRY DATE	FORMULA QUANTITY	QUANTITY USED	PREPARED	CHECKED
Azathioprine 50 mg tablets				20 tablets			
Ora-Blend	Paddock Labs			Qs to 20 mL			

Risk Summary:

This compound is NIOSH-listed, hazardous.

Always follow policies & procedures for risk assessment/NAPRA level as determined by your own pharmacy department.

Equipment and PPE:

- Mortar and pestle
- Graduated cylinder
- Glass stirring rod
- Standard CHEO Level C/oncology satellite PPE

Procedure:

Always follow departments training protocols and policies and procedures that are currently in place.

- 1. Place tablets in mortar and pour a small amount of vehicle over the tablets before levigating.
- 2. Using the pestle, levigate tablets to create a smooth paste.
- **3.** Continue to levigate, adding vehicle in small amounts until the product is liquid enough to transfer to a graduated cylinder.
- 4. Rinse mortar several times with vehicle and add product to the graduated cylinder.
- **5.** QS to final volume with vehicle.
- 6. Stir well and transfer to amber bottle. Label bottle appropriately.
- 7. Before washing, rinse equipment into medication disposal bin, and not directly into sink.

Quality Control:

- Final Appearance: Yellow-tinged, opaque suspension.
- Packaging: amber plastic bottles.
- Storage & BUD: 60 days refrigerated or at room temperature, protect from light.

Sample Label:



Pharmacy Department

Children's Hospital of Eastern Ontario AZATHIOPRINE 50 mg/mL SUSPENSION SHAKE WELL. PROTECT FROM LIGHT. HAZARDOUS. Room Temperature/Refrigerate Quantity: Expiry:

Reference(s):

LOT:

- Nahata MC, Hipple TF, Pediatric Drug Formulations, 4th ed. 2000, pp 17 •
- Allen LV, Erickson MA, Secundum Artem, Stability of Extemporaneously Prepared Pediatric Formulations using Ora-Plus [®] with Ora-Sweet [®] and Ora-Sweet SF [®], Part 1, Volume 5, Number 4, Paddock Laboratories Inc. May 1997
- Jew RK, Mullen RJ, Soo-Hoo W, Extemporaneous Formulations, The Children's Hospital of Philadelphia, • American Society of Health System Pharmacist 2003, pp 6

Formulation Review:

Master Sheet Revision Dates: 4 Feb 98; 7 July 03; 14 Oct 05; 16 Feb 06; 5 Oct 06; Ma 2018.